Presentation is loading. Please wait.

Presentation is loading. Please wait.

SCI Financial Summary All currently active accounts through 31 May 2013 Prof. Alan Fenwick and Kieran Bird Schistosomiasis Control Initiative Advisory.

Similar presentations


Presentation on theme: "SCI Financial Summary All currently active accounts through 31 May 2013 Prof. Alan Fenwick and Kieran Bird Schistosomiasis Control Initiative Advisory."— Presentation transcript:

1 SCI Financial Summary All currently active accounts through 31 May 2013 Prof. Alan Fenwick and Kieran Bird Schistosomiasis Control Initiative Advisory Board Meeting 2013

2 SCI Account summary 1 OF 3 - Implementation SCI Account summary (Implementation) 31/05/2013 AccountFunderStart Date End Date Award NameAward Expended including commitments BalanceExpended % P10348BMGF II01/10/200631/12/2012Integrated Health package£5,306,706£5,243,704£63,00299% P34831DFID01/10/201001/03/2016NTD Treatment 8 countries£10,537,440£7,336,731£3,200,70970% P36980Burundi01/06/201101/05/2014 Schistosomiasis and STH in Burundi£1,040,000£768,897£271,10374% P41895END fund01/03/201201/02/2015 Rwanda Phase II programme£355,441£340,647£14,79496% TOTAL IMPLEMENTATION GRANTS£17,239,587£13,689,979£3,549,60879%

3 SCI Account summary 2 OF 3 – Operational research SCI Account summary (Operational research) 31/05/2013 AccountFunderStart Date End Date Award NameAward Expended including commitments BalanceExpended % P36690 BMGF/Univ Georgia01/11/201001/10/2013SCORE Niger Study 1£186,345£181,395£4,95097% P32154 BMGF/Univ Georgia01/11/201001/10/2013SCORE Niger Study 2£370,386£361,398£8,98898% P32169 BMGF/Univ Georgia01/11/201001/10/2013 SCORE Mozambique Study£368,030£318,152£49,87886% P34213BMGF01/11/201001/10/2014Control of Cysticercosis£957,372£844,753£112,61988% P43408CIFF01/11/201230/04/2014Operational Research£508,500£28,753£479,7476% TOTAL RESEARCH FUNDING£2,390,633£1,734,450£656,18373%

4 SCI Account summary 3 OF 3 – Unrestricted Funds SCI Account summary (Unrestricted funds) 31/05/2013 AccountFunderStart Date End Date Award NameAward Expended including commitments BalanceExpended % L24009Donations01/11/2011 N/A Unrestricted private donations£2,269,311£908,095£1,361,21640% P10099IC Trust01/11/2006N/ASCI Activities£362,883£341,749£21,13494% IC Trust reserves£198,999£0£198,9990% TOTAL UNRESTRICTED FUNDS£2,831,192£1,249,844£1,581,34844%

5 Implementation activities Gates award Gates (#36202). Core funding for SCI (since 2006) and the evaluation of integrated control of Neglected Tropical Diseases in Africa Total funds received US$ 9,975,810 Total interest £ 18,860 No cost extension 31 December 2012 Final report submitted Feb 2013 Unspent & unassigned available balance £70,334, SCI in discussion with BMGF to transfer to Cysticercosis award.

6 Implementation activities: DFID - Integrated Control of Schistosomiasis and Intestinal Helminths in sub-Saharan Africa (ICOSA) SCI is service provider to the £25m DFID ICOSA programme to deliver 75 million treatments in 8 African countries (Crown Agents £14.5m SCI £10.5m) Awarded The target is to reduce schistosomiasis and STH in selected African countries, working in close collaboration with national governments and other donor and international agencies involved in the control of NTDs. A six year contract from October 2010 to March SCI - £ million (with Liverpool CNTD as sub) Commodities (drugs and equipment) to be procured under the project will be up to £14.5 million (Crown Agents) A total annual spend ceiling of £5 million

7 DFID - Integrated Control of Schistosomiasis and Intestinal Helminths in sub-Saharan Africa (ICOSA) Overseas country budgets – FY4 (2013/14)

8 DFID - Integrated Control of Schistosomiasis and Intestinal Helminths in sub-Saharan Africa (ICOSA) Actual spend analysis by category, to 31 May 2013

9 DFID Phase II - Integrated Control of Schistosomiasis and Intestinal Helminths in sub-Saharan Africa (ICOSA) Phase II In January 2012 DFID announced their intention to award additional funding for ICOSA from 2013 – The timetable is : DFID appointed consultants are currently finalising the business case, to be submitted to the Secretary of State (by Sept 2013). We have proposed (subject to negotiation) If approved the new target will be over 200 million treatments in the existing 8 countries plus new programmes in Ethiopia and DRC 2013/142014/152015/162016/17Total SCI TOTAL£2,125,294£3,604,538£4,327,890£6,567,921£16,625,641 TOTAL CROWN AGENTS£3,183,000£2,983,000£2,110,388£97,971£8,374,359 TOTAL£5,308,294£6,587,538£6,438,277£6,665,892£25,000,000

10 Implementation activities Burundi & Rwanda, Schisto & STH Burundi Funding is in place to continue the national treatment campaigns in Burundi for the next 3 years. Total budget £1,040,000 plus Gift Aid, received via IC Trust Rwanda Funding is in place to continue the national treatment campaigns in Rwanda for the next 3 years from the ENDFUND Total approved budget is US$1,643,507 over 3 years starting First tranche of funds received in the sum of US$450, % of these funds will go to the country for implementation.

11 Implementation - Burundi & Rwanda (as at May 31 st 2013) BurundiRwanda

12 Operational Research SCI - SCORE – at University of Georgia (funded by Gates) In January 2011, SCI were awarded three SCORE studies TITLE: Studies of Gaining and Sustaining Control of Schistosomiasis " Study: Schistosoma haematobium: Gaining and Sustaining Control of Schistosomiasis in Capdelgado, Mozambique "Study: Schistosoma haematobium: Gaining and Sustaining Control of Schistosomiasis in Kollo and Say Districts, Niger "Study: Schistosoma Haematobium: Gaining and Sustaining Control of Schistosomiasis in Loga District, Niger Research subcontracts have been executed with RISEAL Niger and Catholic University of Mozambique Total Anticipated SCORE funds 2010 to US$1.245 million. Initial 3 year budget funding originally agreed, the final 2 year extensions for both countries are currently being finalised with SCORE.

13 Operational research SCI - SCORE – budget v actual cost, as 31 May 2013

14 Operational Research SCI – Gates, Control of Cysticercosis in sub Saharan Africa In November 2010, SCI, were awarded a BMGF contract: TITLE: “ Control of Cysticercosis in sub Saharan Africa” P.I. Dr Wendy Harrison Total approved budget $ 1.3 million USD Research subcontracts (90% total budget) have been executed; Technical University Munich, US$ 773,410 Institute of Tropical Medicine Antwerp, US$ 141,375 Univ. of Copenhagen, DBL (Danish Bilharziasis Laboratories), US$ 262,585 SCI (10% total budget) provide lead management function and M&E expertise.

15 Operational Research SCI – Gates, Control of Cysticercosis in sub Saharan Africa Budget v actualBy category

16 Operational Research CIFF Childrens Investment Fund Foundation. Operational research in Liberia & Uganda In November 2012, SCI, were awarded a 3 year contract from CIFF: TITLE: T o assist the development of WHO policy regarding the delivery of deworming control programmes on Uganda, Liberia and Malawi. P.I.s Prof Joanne Webster & Dr Wendy Harrison The start date was 1st November The agreed budget is £1,110,000 for 3 years. The first 18 months (Nov12-Apr14) approved budget is £508,500 To be reviewed with regards to renewal/extension. SCI have recently agreed re-aligned framework milestones and timeframe.

17 Operational Research CIFF, CIFF Childrens Investment Fund Foundation. Operational research in Liberia & Uganda Budget v actual, as 31 May 2013

18 Other awards/donations SCI receives some donations into IC Trust. SCI then draws down the funds into an account P by submitting proposals to the IC Trustees P10099 budget v actual, 31 May 2013 Imperial College Trust (formerly Queen’s Gate Trust) is a registered charity (Registered Charity number ) In addition to the above available funds, SCI has reserves in the sum of £198,999 available to draw down from the Trust

19 Other awards/donations Imperial College has provided SCI with another account ( L24009 ) specifically for private donations received direct to IC. To date some £2.26 million of unrestricted private donations have been received into this account since it was set-up in Feb SCI claims Gift Aid where allowable. These unrestricted funds have been used mainly for small scale interventions or “seed money” in emerging countries e.g. Mozambique, Mauritania, Niger, Senegal & Cote D’Ivoire. In addition, £500,000 has been ring-fenced for activity commitments in Ethiopia. The donations include 2 x $250,000 donations from an US Foundation “Good Ventures” The first of 5 annual anonymous private donations (via IC Trust) for Ethiopia implementation in the sum of £100,000 per annum for 5 years Over $500,000 sent from Givewell for the second year running – via IC Foundation in USA Monthly bankers orders from over 300 people bringing in approximately £10,000 per month

20 Other awards/donations Awards currently in the pipeline or being set-up include: END fund – Yemen, SCI have been awarded a grant for $150,000 for 2013 to support the national Mass Drug Administration program in Yemen VITOL – have awarded SCI $130,000 for Cote D'Ivoire, integrated mapping & ICT activities. NTDs were highlighted on Red Nose Day in March 2013, and so Comic Relief may award their first ever grant to control NTDs Sightsavers, have signed a technical assistance agreement for £85,000 SCI has assisted Sightsavers win a £10 million award from DFID for NTD control in Northern Nigeria. SCI is also assisting Sightsavers with work in mapping schisto and STH in N. Nigeria

21 Publicity and advocacy SCI has so far retained its position as a top rated charity by “Giving what we can”www.givingwhatwecan.orgwww.givingwhatwecan.org SCI is one of the top three international charities recommended by in USA (they review their recommendation annually) These recommendations have highlighted SCI internationally, illustrated financial transparency and led to increased donations. See recent Guardian article evaluators-assess-charitieshttp://www.guardian.co.uk/voluntary-sector-network/2013/jun/11/charity- evaluators-assess-charities However it is imperative for the future of SCI that we continue to perform and be transparent if we want to retain our recommendations from these evaluation sites.

22 Finally… Please see our newsletter at and a promotional video at Thank you


Download ppt "SCI Financial Summary All currently active accounts through 31 May 2013 Prof. Alan Fenwick and Kieran Bird Schistosomiasis Control Initiative Advisory."

Similar presentations


Ads by Google